Oxford Biomedica PLC Chief Secretary to the Treasury visits OXB
24 February 2015 - 2:36AM
RNS Non-Regulatory
TIDMOXB
Oxford Biomedica PLC
23 February 2015
Chief Secretary to the Treasury visits Oxford BioMedica
Oxford, UK - 23 February 2015: Oxford BioMedica plc (LSE: OXB),
("OXB" or "the Company") a leading gene and cell therapy company,
today welcomed the Rt Hon Danny Alexander, Chief Secretary to the
Treasury, to its laboratories on the Oxford Science Park.
During the visit, the Chief Secretary to the Treasury toured the
Company's process development lab, a facility dedicated to the
development of robust and scalable manufacturing processes for gene
and cell based therapies that have the potential to transform
medicine.
In recognition of Oxford BioMedica's leading position in gene
and cell therapy, the Company was awarded a combination of grant
and loan funding worth GBP7.1 million under the UK Government's
Advanced Manufacturing Supply Chain Initiative (AMSCI) in 2013. The
funding was awarded to the Company to support Oxford BioMedica in
becoming a world-leader and UK Centre of Excellence in the
manufacture and supply chain of gene and cell based therapies.
Chief Secretary to the Treasury Danny Alexander said: "Our
science base is one of the UK's most prized economic assets and I
want us to remain a world-leader in science. That's why this
government has committed GBP345m to the Advanced Manufacturing
Supply Chain Initiative (AMSCI) to help strengthen and grow
advanced manufacturing supply chains in the UK.
"It's great to visit Oxford BioMedica, which has invested AMSCI
funding into becoming a world leader in the biopharmaceutical
sector, creating new highly skilled local jobs that contribute to a
stronger regional and national economy."
John Dawson, Chief Executive Officer of Oxford BioMedica, said:
"Positive actions in life sciences by the government in recent
years have helped to create a much more encouraging funding
environment in the UK. Specific items such as R&D tax breaks
and the Innovate UK fund have been enormously helpful and the AMSCI
funding in particular has undoubtedly helped us to win a major
contract with Novartis in the field of cell therapy last year."
-Ends-
For further information, please contact:
Oxford BioMedica plc: Tel: +44 (0)1865
John Dawson, Chief Executive Officer 783 000
Tim Watts, Chief Financial Officer
Media Enquiries:
Mary-Jane Elliott/ Matthew Neal/ Chris Welsh/ Tel: +44 (0)20
Laura Thornton 3709 5700
Consilium Strategic Communications
Notes for editors
About Oxford BioMedica(R)
Oxford BioMedica plc (LSE: OXB) is a leading gene and cell
therapy company with an unrivalled portfolio of gene therapy
products in development and a platform of exclusive and pioneering
technologies with which it designs, develops and manufactures
unique gene-based medicines for some of world's largest
pharmaceutical companies. Leveraging its proprietary LentiVector(R)
IP and gene delivery system technology platform and unique tumour
antigen (5T4), Oxford BioMedica is advancing its pipeline of seven
gene therapy products addressing diseases for which there are
currently no treatments or that are inadequately treated today,
including ocular and central nervous system disorders. OXB
Solutions, the Company's industry-leading manufacturing and
development business, provides services to collaborators and
partners working in gene and cell therapy, including Novartis and
Immune Design Corp. In addition, the Company has licenced products
and IP to Sanofi, Pfizer, MolMed, Sigma-Aldrich, Biogen Idec,
Emergent BioSolutions and ImaginAb. Further information is
available at www.oxfordbiomedica.co.uk and www.oxbsolutions.co.uk
.
This information is provided by RNS
The company news service from the London Stock Exchange
END
NRAPKNDNPBKDDBB
Oxford Biomedica (LSE:OXB)
Historical Stock Chart
From Apr 2024 to May 2024
Oxford Biomedica (LSE:OXB)
Historical Stock Chart
From May 2023 to May 2024